STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Aug. 31, 2015	Aug. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (1,134,826)	$ (1,567,578)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	342	342
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph. D.	1,030,153	1,378,412
Changes in operating assets and liabilities
Accounts payable	(7,146)	(880)
Accrued liabilities	16	(14,845)
NET CASH USED IN OPERATING ACTIVITIES	(111,461)	(204,549)
CASH FLOWS FROM FINANCING ACTIVITIES
Contribution of capital	109,683	210,129
NET CASH PROVIDED BY FINANCING ACTIVITIES	109,683	210,129
NET (DECREASE) INCREASE IN CASH	(1,778)	5,580
CASH AT BEGINNING OF PERIOD	2,280	229
CASH AT END OF PERIOD	$ 502	$ 5,809